DANCANN PHARMA A/S |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.002200 DKK | 0.00% |
|
0.00% | +10.00% |
| 01-07 | Dancann Pharma proposes a 1:1,000 reverse split | FW |
| 01-06 | DanCann Pharma to Propose Share Consolidation to Reduce Costs | MT |
Sales 2023 by Business Segment
Sales 2023 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
Biological Products | |||||
Pharmaceuticals | -422K | -4.83M | 874K | 7.19M | 7.15M |
Total Assets | 1.47M | 49.55M | 68.99M | 73.7M | 17.39M |
Interest Expense | -11.64K | -140K | -1.26M | -3.02M | -2.33M |
Income Tax Expense | -139K | -1.73M | -3.44M | -2.19M | 21K |
CAPEX | -1.01M | -18.75M | -32.4M | -8.27M | -7K |
EBT | -638K | -5.99M | -15.18M | -18.25M | -62.24M |
Gross Profit | - | - | -6.49M | -5.67M | -3.44M |
D&A | 7.88K | 94.12K | 890K | 2.23M | 3.38M |
Operating Income | -627K | -5.87M | -14.51M | -16.42M | -60.12M |
Net Income | -500K | -4.25M | -11.75M | -16.06M | -62.26M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
Denmark | -422K | -4.83M | 874K | 7.19M | 7.15M |
Total Assets | 1.47M | 49.55M | 68.99M | 73.7M | 17.39M |
Interest Expense | -11.64K | -140K | -1.26M | -3.02M | -2.33M |
Income Tax Expense | -139K | -1.73M | -3.44M | -2.19M | 21K |
D&A | 7.88K | 94.12K | 890K | 2.23M | 3.38M |
CAPEX | -1.01M | -18.75M | -32.4M | -8.27M | -7K |
Gross Profit | - | - | -6.49M | -5.67M | -3.44M |
Net Income | -500K | -4.25M | -11.75M | -16.06M | -62.26M |
EBT | -638K | -5.99M | -15.18M | -18.25M | -62.24M |
Operating Income | -627K | -5.87M | -14.51M | -16.42M | -60.12M |
- Stock Market
- Equities
- DANCAN Stock
- Financials Dancann Pharma A/S
- Business Segments
MarketScreener is also available in this country: United States.
Switch edition